OLX-103

N/A

Report date: 2026/03/13 20:02:36

NME

Base Information

Drug NameOLX-103

Drug Alias NameCell penetrating asymmetric siRNA (OliX Pharmaceuticals)self-delivering RNAi agent for atopic dermatitis(OliX Pharmaceuticals)

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionConnective tissue growth factor inhibitors

TargetsConnective tissue growth factor

Therapy Area/IndicationsDermatitis, Atopic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOlix Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesOlix Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsDermatitis, Atopic

Inactive IndicationsN/A

Other Information

ATC CodeN/A